From Our 2009 Archives
Nasal Spray May Kill Cold Virus
Latest MedicineNet News
Virus Levels Drop Faster in Volunteers Given Oxymetazoline Spray
Reviewed By Louise Chang, MD
In a new study, viral levels dropped more quickly than expected in volunteers treated with oxymetazoline nasal sprays, says Birgit Winther, MD, PhD, of the University of Virginia in Charlottesville.
Winther tells WebMD that previous research in test tubes suggested that oxymetazoline had an antiviral effect against rhinovirus, which causes the common cold.
As the next step, she and colleagues infected 94 young healthy adult volunteers with the rhinovirus.
Three hours later, "before they really got sick," half were randomly assigned to receive oxymetazoline nasal spray and the other half were given a saline spray. The volunteers received one puff of either spray into each nostril three times daily for five days.
Cold Virus Levels Drop Quickly in Volunteers Given Oxymetazoline
If no medication is given, "you would expect viral levels in nasal secretions to peak two to three days after infection," Winther says. That's just what happened in the volunteers who were treated with saline.
But in volunteers given oxymetazoline, rhinovirus levels in nasal secretions started to drop by day two, she says.
By the fourth day after infection with rhinovirus, however, viral levels were lower -- and the same -- in both groups.
The new study was presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy.
Long-Term Use Has Rebound Effect
Sprays containing oxymetazoline are sold under a variety of trade names, including Afrin, Dristan 12-Hour Nasal Spray, Duramist Plus, and Vicks Sinex 12 Hour Nasal Spray.
Michael Ison, MD, an infectious diseases expert at Northwestern University in Chicago who moderated the session at which the findings were presented, says he isn't sure that the quick dip in viral levels in volunteers given oxymetazoline "is clinically meaningful."
The sprays "definitely provide symptom relief," but further study is needed to confirm an antiviral effect, he tells WebMD.
SOURCES: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Sept. 12-15, 2009. Birgit Winther, MD, PhD, associate professor, department of otolaryngology, University of Virginia, Charlottesville. Michael Ison, MD, division of infectious diseases, Northwestern University Feinberg School of Medicine, Chicago.
©2009 WebMD, LLC. All Rights Reserved.
- Allergic Skin Disorders
- Bacterial Skin Diseases
- Bites and Infestations
- Diseases of Pigment
- Fungal Skin Diseases
- Medical Anatomy and Illustrations
- Noncancerous, Precancerous & Cancerous Tumors
- Oral Health Conditions
- Papules, Scales, Plaques and Eruptions
- Scalp, Hair and Nails
- Sexually Transmitted Diseases (STDs)
- Vascular, Lymphatic and Systemic Conditions
- Viral Skin Diseases
- Additional Skin Conditions